ValuEngine Upgrades Minerva Neurosciences (NERV) to Sell

Minerva Neurosciences (NASDAQ:NERV) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Thursday.

A number of other brokerages have also weighed in on NERV. BidaskClub upgraded shares of Minerva Neurosciences from a “hold” rating to a “buy” rating in a research report on Friday, April 6th. Zacks Investment Research lowered shares of Minerva Neurosciences from a “buy” rating to a “hold” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Minerva Neurosciences presently has an average rating of “Hold” and an average price target of $12.75.

Minerva Neurosciences traded up $0.90, reaching $7.40, during trading hours on Thursday, according to Marketbeat.com. 494,400 shares of the company were exchanged, compared to its average volume of 177,515. Minerva Neurosciences has a 1 year low of $6.55 and a 1 year high of $6.80. The company has a market capitalization of $257.68 million, a PE ratio of -6.85 and a beta of 1.43.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). research analysts predict that Minerva Neurosciences will post -1.46 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the business. Franklin Resources Inc. boosted its position in Minerva Neurosciences by 3.6% during the fourth quarter. Franklin Resources Inc. now owns 1,235,000 shares of the biopharmaceutical company’s stock worth $7,472,000 after purchasing an additional 42,700 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Minerva Neurosciences by 64.7% during the third quarter. Schwab Charles Investment Management Inc. now owns 57,000 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 22,400 shares during the period. Goldman Sachs Group Inc. boosted its position in Minerva Neurosciences by 47.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 40,835 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 13,199 shares during the period. Ascend Capital LLC boosted its position in Minerva Neurosciences by 4.8% during the fourth quarter. Ascend Capital LLC now owns 819,347 shares of the biopharmaceutical company’s stock worth $4,957,000 after purchasing an additional 37,659 shares during the period. Finally, Sphera Funds Management LTD. boosted its position in Minerva Neurosciences by 24.0% during the fourth quarter. Sphera Funds Management LTD. now owns 775,000 shares of the biopharmaceutical company’s stock worth $4,689,000 after purchasing an additional 150,000 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit